Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Ca<sup>2+</sup> signaling and the Hippo pathway: Intersections in cellular regulation

Sayedyahossein S., Thines L., Sacks DB.

Narrative Review on Hip, published in Cell Signal (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cell Signal (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37549859
PMCID
PMC10529277
DOI
10.1016/j.cellsig.2023.110846
Citations
16

Abstract (original English)

The Hippo signaling pathway is a master regulator of organ size and tissue homeostasis. Hippo integrates a broad range of cellular signals to regulate numerous processes, such as cell proliferation, differentiation, migration and mechanosensation. Ca 2+ is a fundamental second messenger that modulates signaling cascades involved in diverse cellular functions, some of which are also regulated by the Hippo pathway. Studies published over the last five years indicate that Ca 2+ can influence core Hippo pathway components. Nevertheless, comprehensive understanding of the crosstalk between Ca 2+ signaling and the Hippo pathway, and possible mechanisms through which Ca 2+ regulates Hippo, remain to be elucidated. In this review, we summarize the multiple intersections between Ca 2+ and the Hippo pathway and address the biological consequences.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Signal TransductionCell DifferentiationCell ProliferationHippo Signaling PathwayProtein Serine-Threonine Kinases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research